Revenue GrowthThe company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.

Gross Profit MarginA strong gross profit margin suggests effective cost management and pricing power, which can support future profitability as the company scales its operations.

Cash Flow GrowthPositive free cash flow growth indicates improving cash generation ability, which is essential for funding R&D and supporting strategic initiatives without relying heavily on external financing.

Bears Say

Profitability ChallengesOngoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.

Operating Cash FlowNegative operating cash flow suggests the company is not generating sufficient cash from its core operations, potentially limiting its ability to sustain growth and meet financial obligations.

Return On EquityNegative return on equity reflects inefficiencies in using shareholder funds to generate profits, which could deter investors and affect the company's ability to raise capital.

9Y4 FAQ

What was Ryvu Therapeutics SA’s price range in the past 12 months?

Ryvu Therapeutics SA lowest stock price was €4.17 and its highest was €8.09 in the past 12 months.

What is Ryvu Therapeutics SA’s market cap?

Ryvu Therapeutics SA’s market cap is €137.94M.

When is Ryvu Therapeutics SA’s upcoming earnings report date?

Ryvu Therapeutics SA’s upcoming earnings report date is Mar 17, 2026 which is in 28 days.

How were Ryvu Therapeutics SA’s earnings last quarter?

Ryvu Therapeutics SA released its earnings results on Nov 20, 2025. The company reported -€0.254 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.254.

Is Ryvu Therapeutics SA overvalued?

According to Wall Street analysts Ryvu Therapeutics SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ryvu Therapeutics SA pay dividends?

Ryvu Therapeutics SA does not currently pay dividends.

What is Ryvu Therapeutics SA’s EPS estimate?

Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ryvu Therapeutics SA have?

Ryvu Therapeutics SA has 23,120,148 shares outstanding.

What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?

Ryvu Therapeutics SA reported an EPS of -€0.254 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.147%.

Which hedge fund is a major shareholder of Ryvu Therapeutics SA?

Currently, no hedge funds are holding shares in DE:9Y4

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ryvu Therapeutics SA

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.